Top 5 Stocks To Own For 2014

NEW YORK (TheStreet) -- The September Federal Open Market Committee meeting will be this week and months of speculation over stimulus cuts will finally be priced into markets.

Investors expect a cut in the Federal Reserve bond-buying program, and the amount of the cut is what will move markets. The expectation sits at around a $10-$15 billion cut from the current $85 billion monthly purchases of Treasuries and mortgage-backed securities. If the Fed deviates from this path by a large margin, it should spur heavy volume of bond buying or selling. [Read: The Deal: White House Defends Financial Crisis Response]

The chart below is of iShares Barclays 20+ Year Treasury Bond (TLT). The long-dated Treasury has sold off heavily since its peak in May as investors have come to terms with higher interest rates and sold off bonds to the point that a stimulus cut is now expected.

Top High Tech Stocks To Own Right Now: HeartWare International Inc (HTWR)

Heartware International, Inc. (HeartWare), incorporated on June 25, 2010, develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure. The HeartWare Ventricular Assist System (the HeartWare System), which includes a ventricular assist device (VAD), or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients in the advanced stage of heart failure. The core of the HeartWare System is a continuous flow blood pump, the HVAD Pump, which is a full-output device capable of pumping up to 10 liters of blood per minute. The HeartWare System is designed to be implanted adjacent to the heart, avoiding the abdominal surgery generally required to implant similar devices. In August 2012, it acquired World Heart Corporation. As of December 31, 2012, the HeartWare System has been implanted outside of the United States at approximately 168 health care sites in 28 countries. In December 2013, HeartWare International Inc acquired CircuLite, Inc.

Proprietary Pump Technology

The HeartWare System is full-output centrifugal pump designed to be implanted in the chest, directly adjacent to the heart. At the core of the Company�� technology platform is its hybrid system for suspending the impeller, which is the only moving part within the pump. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller, which circulates a cushion of

blood. Once power is applied to the device and the impeller begins to rotate, there are no points of mechanical contact within the pump, thus providing a completely wearless pumping system.

The HeartWare System

The HeartWare System consists of the HVAD Pump, a small, permanently implantable VAD, patient accessories and surgical tools. The HVAD Pump is capable of generating up to 10 liters of blood flow per minute. With a displaced v! olume of only 50 cubic centimeters and a mass of 140 grams, the HVAD Pump is the only full-output pump implantable in the pericardial space, directly adjacent to the heart. It is also the only pump designed to be implanted above the diaphragm in all eligible patients.

The HeartWare MVAD

The miniaturized ventricular assist device (MVAD) is a miniaturized blood pump intended for chronic heart failure patients. The device is a full-output axial flow pump with a fully suspended rotor and a displacement volume approximately one-third that of the HVAD Pump.

The Company competes with Thoratec Corporation, Jarvik Heart, MicroMed Technology, Inc, Berlin Heart AG, Terumo Heart, Inc., Sunshine Heart, Inc and CircuLite, Inc., Evaheart Medical USA, Inc.

Advisors' Opinion:

• [By Todd Campbell]

  Competing for heart pump market share
  Abiomed's products provide circulatory support for up to six hours and are designed for use in cardiac cath labs or during heart surgery, but competitors Thoratec (NASDAQ: THOR  ) and Heartware (NASDAQ: HTWR  ) target the intermediate- and long-term-use market instead.

• [By Lauren Pollock]

  Medical device company HeartWare International Inc.(HTWR) issued a revenue forecast that fell short of market expectations.

  Intrepid Potash Inc.(IPI), the largest potash producer in the U.S., plans to cut its workforce by 7% and cut executive compensation as part of a plan to trim costs in reaction to weaker prices for the fertilizer ingredient.

• [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]

  HeartWare International Inc.(HTWR) said it received a warning letter from the U.S. Food and Drug Administration, citing concerns about procedures for validating device design and other issues.

Top 5 Stocks To Own For 2014: Obagi Medical Products Inc.(OMPI)

Obagi Medical Products, Inc., a specialty pharmaceutical company, develops, markets, and sells topical aesthetic and therapeutic prescription skin care systems. It offers Obagi Nu-Derm System, including prescription and OTC drugs that are used for the treatment of fine lines, wrinkles, acne, photo damage, hyperpigmentation, melasma, laxity, and skin sallowness; Obagi Condition and Enhance Systems that are used before and after surgical and non-surgical cosmetic procedures; Obagi-C Rx System comprises Vitamin C with 4% hydroquinone system to treat skin conditions resulting from sun damage and the oxidative damage of free radicals; and Professional-C products consisting of Vitamin C serums for the treatment of antioxidant protection, fine lines, wrinkles, and hyperpigmentation. The company also provides ELASTIderm Eye and D�olletage, which increases the elasticity and skin tone of eyes, face, neckline, and chest; ELASTILash Eyelash Solution that enhances the appearance of thickness and fullness of eyelashes; CLENZIderm M.D. Systems and Tretinoin for treating acne; and Obagi Rosaclear System used for the treatment of rosacea. In addition, it offers Refissa and Blue Peel RADIANCE used for the treatment of fine facial lines, hyperpigmentation, and tactile roughness; Metronidazole used for the treatment of rosacea; Obagi Blue Peel Essential Kit used for the treatment of fine lines, wrinkles, and hyperpigmentation. Further, the company licenses non-prescription product concepts under the Obagi trademark to a Japanese-based pharmaceutical company for sale through consumer distribution channels in Japan. Obagi Medical Products, Inc. sells its products through sales force and distribution partners in the United States, North and Central America, Europe, the Middle East, and Asia to dermatologists, plastic surgeons, and other physicians that are focused on aesthetic and therapeutic skin care. The company was founded in 1988 and is headquartered in Lon g Beach, California.

Advisors' Opinion:

• [By David Williamson]

  Though many excited traders had hoped to see the bidding war continue between Valeant Pharmaceuticals (NYSE: VRX  ) and Merz over Obagi Medical Products (NASDAQ: OMPI  ) and a subsequent run-up in the stock price of the smaller dermatological products maker, Merz has now walked away from the table, leaving the highly acquisitive Valeant the victor. In this video, Motley Fool health care analyst David Williamson gives us some background on these companies and tells us how Valeant plans to profit from the deal, and describes for investors why this is a win both for Obagi and for Valeant.

• [By Keith Speights]

  "Bidness" is good
  Last week, Obagi Medical Products (NASDAQ: OMPI  ) made our list of humongous performers after Valeant Pharmaceuticals� (NYSE: VRX  ) announced a $344 million bid for the company. This week saw a bidding frenzy, with Obagi shares jumping another 29%.

Top 5 Stocks To Own For 2014: Gem International Resources Inc (GI)

Gem International Resources Inc. (Gem International) is a Canada-based junior natural resource company. The Company is primarily engaged in the acquisition, exploration and development of mineral properties with its principal focus on diamond, gold and other precious metals. The Company is in exploration-stage and has interest in mineral properties located in Canada and Tanzania. The Company owns more than 105 mining claims comprised of approximately 240,172 acres located in the Lac de Gras Property located approximately 260 kilometers northeast of Yellowknife, Northwest Territories. Its Kolandoto Diamond Property is located in the Shinyanga region of Tanzania. Kolandoto property consists of approximately10 primary mining licenses covering a total area of approximately 247 acres. The Shinyanga Property consists of more than 105 primary mining licenses covering a total area of approximately 2,743 acres. Advisors' Opinion:

• [By Victor Selva]

  In January 2014, Forest acquired Toronto-based Aptalis, a privately held U.S.-based specialty Gastrointestinal (GI) and Cystic Fibrosis Company, for $2.9 billion in cash from its shareholders, including TPG, the global private investment firm. The deal looks attractive especially keeping in mind the fact that Namenda will be facing generic competition from 2015. The acquisition will also give Forest the opportunity to build its presence in Europe and strengthen its GI and CF portfolios.

Top 5 Stocks To Own For 2014: Vestas Wind Systems A/S (VWS)

Vestas Wind Systems A/S is a Denmark-based company active within the wind power industry. The Company operates within four business areas: Finance, Sales, Manufacturing & Global Sourcing, and Technology & Service Solutions. The Finance business area focuses on business support services. The Sales business area is divided into six geographical units: Americas, Asia Pacific & China, Central Europe, Mediterranean, Northern Europe and Offshore. The Manufacturing & Global Sourcing business area is engaged in the manufacturing of assembly, blades, components, controls and generators. The Technology & Service Solutions business area is responsible for the engineering solutions, platform and product management, as well as service engineering, among others. As of December 31, 2012, the Company operated globally through a network of subsidiaries located in Denmark, Germany, Italy, China, the United States, Spain, Estonia, Sweden and Norway. Advisors' Opinion:

• [By Tom Stoukas]

  Vestas Wind Systems A/S (VWS) surged 11 percent to 66.30 kroner, its highest price since February 2012. Credit Suisse Group AG raised the world�� biggest wind-turbine maker to neutral from underperform, citing benefits from cost cuts.

• [By Pato Kehoe]

  Within the power infrastructure segment, GE is especially keen on advancing in clean-energy products, such as gas and wind turbines. Wind turbines have contributed significantly to generating a solid competitive advantage, even allowing the firm to surpass the Danish industry giant Vestas Wind Systems (VWS), thanks to superior customer care and manufacturing expertise. Hence, the road seems paved for continued success in this new industry sector, which is bound to continue growing as clean energy becomes more popular.